JAGUAR HEALTH, INC. Operating Income
JAGUAR HEALTH, INC. (JAGX) reported Operating Income of -$7.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-19
- JAGUAR HEALTH, INC. operating income (loss) for the quarter ending 2026-06-30 was -$7.60M.
- JAGUAR HEALTH, INC. operating income (loss) for the quarter ending 2026-03-31 was $10.18M.
- JAGUAR HEALTH, INC. operating income (loss) for the quarter ending 2025-12-31 was -$21.24M.
- JAGUAR HEALTH, INC. operating income (loss) for the quarter ending 2025-09-30 was -$7.24M.
- JAGUAR HEALTH, INC. operating income (loss) for fiscal 2025 was -$45.91M.
- JAGUAR HEALTH, INC. operating income (loss) for fiscal 2024 was -$30.83M.
- JAGUAR HEALTH, INC. operating income (loss) for fiscal 2023 was -$34.29M.
- JAGUAR HEALTH, INC. operating income (loss) for fiscal 2022 was -$34.41M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.60M 10-Q · filed 2026-08-19 | $2.58M 10-Q · filed 2026-08-19 | -$18.66M derived: sum of 3 quarters · filed 2026-08-19 | -$25.89M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2026-03-31 | $10.18M 10-Q · filed 2026-05-20 | -$11.06M derived: sum of 2 quarters · filed 2026-05-20 | -$18.30M derived: sum of 3 quarters · filed 2026-05-20 | -$26.30M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-12-31 | -$21.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$28.48M derived: sum of 2 quarters · filed 2026-04-07 | -$36.49M derived: sum of 3 quarters · filed 2026-08-19 | -$45.91M 10-K · filed 2026-04-07 | ||||
| 2025-09-30 | -$7.24M 10-Q · filed 2025-11-14 | -$15.24M derived: sum of 2 quarters · filed 2026-08-19 | -$24.67M 10-Q · filed 2025-11-14 | -$32.82M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-06-30 | -$8.01M 10-Q · filed 2026-08-19 | -$17.43M 10-Q · filed 2026-08-19 | -$25.59M derived: sum of 3 quarters · filed 2026-08-19 | -$32.85M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-03-31 | -$9.42M 10-Q · filed 2026-05-20 | -$17.58M derived: sum of 2 quarters · filed 2026-05-20 | -$24.84M derived: sum of 3 quarters · filed 2026-05-20 | -$32.04M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | -$8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$15.42M derived: sum of 2 quarters · filed 2026-04-07 | -$22.62M derived: sum of 3 quarters · filed 2026-04-07 | -$30.83M 10-K · filed 2026-04-07 | ||||
| 2024-09-30 | -$7.26M 10-Q · filed 2025-11-14 | -$14.46M derived: sum of 2 quarters · filed 2025-11-14 | -$22.67M 10-Q · filed 2025-11-14 | -$30.23M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | -$7.20M 10-Q · filed 2025-08-14 | -$15.41M 10-Q · filed 2025-08-14 | -$22.97M derived: sum of 3 quarters · filed 2025-08-14 | -$31.76M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$8.21M 10-Q · filed 2025-05-15 | -$15.77M derived: sum of 2 quarters · filed 2025-05-15 | -$24.56M derived: sum of 3 quarters · filed 2025-05-15 | -$32.66M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.34M derived: sum of 2 quarters · filed 2025-03-31 | -$24.45M derived: sum of 3 quarters · filed 2025-03-31 | -$34.29M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$8.79M 10-Q · filed 2024-11-13 | -$16.89M derived: sum of 2 quarters · filed 2024-11-13 | -$26.73M 10-Q · filed 2024-11-13 | -$33.02M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$8.10M 10-Q · filed 2024-08-13 | -$17.95M 10-Q · filed 2024-08-13 | -$24.23M derived: sum of 3 quarters · filed 2024-08-13 | -$34.13M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$9.85M 10-Q · filed 2024-05-14 | -$16.13M derived: sum of 2 quarters · filed 2024-05-14 | -$26.03M derived: sum of 3 quarters · filed 2024-05-14 | -$32.51M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$16.18M derived: sum of 2 quarters · filed 2024-04-01 | -$22.66M derived: sum of 3 quarters · filed 2024-04-01 | -$34.41M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$9.90M 10-Q · filed 2023-11-14 | -$16.38M derived: sum of 2 quarters · filed 2023-11-14 | -$28.13M 10-Q · filed 2023-11-14 | -$38.95M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$6.48M 10-Q · filed 2023-08-14 | -$18.23M 10-Q · filed 2023-08-14 | -$29.05M derived: sum of 3 quarters · filed 2023-08-14 | -$38.58M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$11.75M 10-Q · filed 2023-05-15 | -$22.58M derived: sum of 2 quarters · filed 2023-05-15 | -$32.10M derived: sum of 3 quarters · filed 2023-05-15 | -$43.69M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$10.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$20.35M derived: sum of 2 quarters · filed 2023-03-24 | -$31.93M derived: sum of 3 quarters · filed 2023-03-24 | -$40.71M 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | -$9.53M 10-Q · filed 2022-11-14 | -$21.11M derived: sum of 2 quarters · filed 2022-11-14 | -$29.89M 10-Q · filed 2022-11-14 | -$35.04M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$11.58M 10-Q · filed 2022-08-22 | -$20.35M 10-Q · filed 2022-08-22 | -$25.51M derived: sum of 3 quarters · filed 2022-08-22 | -$30.89M derived: sum of 4 quarters · filed 2022-08-22 | ||||
| 2021-03-31 | -$8.77M 10-Q · filed 2022-05-10 | -$13.93M derived: sum of 2 quarters · filed 2022-05-10 | -$19.31M derived: sum of 3 quarters · filed 2022-05-10 | -$27.76M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$10.54M derived: sum of 2 quarters · filed 2022-03-11 | -$18.99M derived: sum of 3 quarters · filed 2022-03-11 | -$26.65M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | -$5.38M 10-Q · filed 2021-11-17 | -$13.83M derived: sum of 2 quarters · filed 2021-11-17 | -$21.48M 10-Q · filed 2021-11-17 | -$27.30M derived: sum of 4 quarters · filed 2021-11-17 | ||||
| 2020-06-30 | -$8.45M 10-Q · filed 2021-08-13 | -$16.11M 10-Q · filed 2021-08-13 | -$21.93M derived: sum of 3 quarters · filed 2021-08-13 | -$28.66M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$7.65M 10-Q · filed 2021-05-17 | -$13.48M derived: sum of 2 quarters · filed 2021-05-17 | -$20.20M derived: sum of 3 quarters · filed 2021-05-17 | -$30.83M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | -$5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$12.55M derived: sum of 2 quarters · filed 2021-03-31 | -$23.17M derived: sum of 3 quarters · filed 2021-03-31 | -$28.95M 10-K · filed 2021-03-31 | -$28.95M 10-K · filed 2020-04-03 | |||
| 2019-09-30 | -$6.73M 10-Q · filed 2020-11-16 | -$6.73M 10-Q · filed 2019-11-14 | -$17.35M derived: sum of 2 quarters · filed 2020-11-16 | -$23.12M 10-Q · filed 2020-11-16 | -$23.12M 10-Q · filed 2019-11-14 | -$35.23M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | -$10.62M 10-Q · filed 2020-08-13 | -$10.62M 10-Q · filed 2019-08-14 | -$16.40M 10-Q · filed 2020-08-13 | -$16.40M 10-Q · filed 2019-08-14 | -$28.51M derived: sum of 3 quarters · filed 2020-08-13 | -$35.01M derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | -$5.78M 10-Q · filed 2020-05-15 | -$5.78M 10-Q · filed 2019-05-21 | -$17.89M derived: sum of 2 quarters · filed 2020-05-15 | -$24.39M derived: sum of 3 quarters · filed 2020-05-15 | -$31.47M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | -$18.62M derived: sum of 2 quarters · filed 2020-04-03 | -$25.70M derived: sum of 3 quarters · filed 2020-04-03 | -$30.82M 10-K · filed 2020-04-03 | ||||
| 2018-09-30 | -$6.51M 10-Q · filed 2019-11-14 | -$13.59M derived: sum of 2 quarters · filed 2019-11-14 | -$18.71M 10-Q · filed 2019-11-14 | -$39.39M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | -$7.08M 10-Q · filed 2019-08-14 | -$12.21M 10-Q · filed 2019-08-14 | -$32.89M derived: sum of 3 quarters · filed 2019-08-14 | -$40.23M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$5.13M 10-Q · filed 2019-05-21 | -$25.81M derived: sum of 2 quarters · filed 2019-05-21 | -$33.15M derived: sum of 3 quarters · filed 2019-05-21 | -$35.50M derived: sum of 4 quarters · filed 2019-05-21 | ||||
| 2017-12-31 | -$20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$28.02M derived: sum of 2 quarters · filed 2019-04-10 | -$30.37M derived: sum of 3 quarters · filed 2019-04-10 | -$34.25M 10-K · filed 2019-04-10 | ||||
| 2017-09-30 | -$7.34M 10-Q · filed 2018-11-19 | -$9.69M derived: sum of 2 quarters · filed 2018-11-19 | -$13.57M 10-Q · filed 2018-11-19 | -$16.88M derived: sum of 4 quarters · filed 2018-11-19 | ||||
| 2017-06-30 | -$2.35M 10-Q · filed 2018-08-13 | -$6.23M 10-Q · filed 2018-08-13 | -$9.54M derived: sum of 3 quarters · filed 2018-08-13 | -$12.72M derived: sum of 4 quarters · filed 2018-08-13 | ||||
| 2017-03-31 | -$3.88M 10-Q · filed 2018-05-15 | -$7.19M derived: sum of 2 quarters · filed 2018-05-15 | -$10.37M derived: sum of 3 quarters · filed 2018-05-15 | -$13.78M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | -$3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$6.49M derived: sum of 2 quarters · filed 2018-04-09 | -$9.90M derived: sum of 3 quarters · filed 2018-04-09 | -$13.59M 10-K · filed 2018-04-09 | ||||
| 2016-09-30 | -$3.18M 10-Q · filed 2017-11-20 | -$6.59M derived: sum of 2 quarters · filed 2017-11-20 | -$10.27M 10-Q · filed 2017-11-20 | -$14.11M derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-06-30 | -$3.41M 10-Q · filed 2017-08-09 | -$7.09M 10-Q · filed 2017-08-09 | -$10.94M derived: sum of 3 quarters · filed 2017-08-09 | -$13.69M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | -$3.68M 10-Q/A · filed 2017-06-23 | -$7.53M derived: sum of 2 quarters · filed 2017-06-23 | -$10.28M derived: sum of 3 quarters · filed 2017-06-23 | -$13.45M derived: sum of 4 quarters · filed 2017-06-23 | ||||
| 2015-12-31 | -$3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$6.60M derived: sum of 2 quarters · filed 2017-02-15 | -$9.77M derived: sum of 3 quarters · filed 2017-02-15 | -$12.45M 10-K · filed 2017-02-15 | ||||
| 2015-09-30 | -$2.75M 10-Q · filed 2016-11-14 | -$5.92M derived: sum of 2 quarters · filed 2016-11-14 | -$8.60M 10-Q · filed 2016-11-14 | -$10.45M derived: sum of 4 quarters · filed 2016-11-14 | ||||
| 2015-06-30 | -$3.17M 10-Q · filed 2016-08-15 | -$5.85M 10-Q · filed 2016-08-15 | -$7.69M derived: sum of 3 quarters · filed 2016-08-15 | -$10.27M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | -$2.68M 10-Q · filed 2016-05-10 | -$4.52M derived: sum of 2 quarters · filed 2016-05-10 | -$7.10M derived: sum of 3 quarters · filed 2016-05-10 | -$9.04M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | -$4.43M derived: sum of 2 quarters · filed 2016-03-29 | -$6.36M derived: sum of 3 quarters · filed 2016-03-29 | -$8.32M 10-K · filed 2016-03-29 | ||||
| 2014-09-30 | -$2.58M 10-Q · filed 2015-11-13 | -$4.52M derived: sum of 2 quarters · filed 2015-11-13 | -$6.47M 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | -$1.94M 10-Q · filed 2015-08-13 | -$3.89M 10-Q · filed 2015-08-13 | ||||||
| 2014-03-31 | -$1.95M 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |